The Amyloidosis Research Consortium’s Executive Director of Research, Kristen Hsu, discussed the current clinical trial landscape in AL amyloidosis. She reviewed trials currently recruiting patients, trials expecting to share results this year, and trials that are planned to open in the future.
Original Presentation Date:
April 14, 2026
0:00 — Welcome
3:52 — Introduction
5:45 — AL Amyloidosis Overview
10:17 — AL Treatment Approaches
18:19 — Recruiting Trials for Novel AL Therapies
19:09 — ALANIS (antibody-drug conjugate; newly diagnosed AL amyloidosis)
20:47 — IMPACT-AL (bispecific antibody; newly diagnosed AL amyloidosis)
22:45 — REMANTAMIG (trispecific antibody; previously treated AL amyloidosis)
24:50 — LINKER-AL2 (bispecific antibody; relapsed/refractory AL amyloidosis)
27:05 — ETENTAMIG (bispecific antibody; relapsed/refractory AL amyloidosis)
29:19 — ALACRITY (CAR-T cell therapy; relapsed/refractory AL amyloidosis)
33:25 — Planned Trials for Novel AL Therapies
34:04 — PROT-001 (lambda light chain stabilizer; AL amyloidosis)
35:52 — News and Upcoming Milestones for Novel AL Therapies
36:07 — NEXICART-2 (CAR-T cell therapy; relapsed/refractory AL amyloidosis)
37:53 — CARES (anti-fibril antibody; newly diagnosed AL amyloidosis)
41:19 — AT-02 (anti-fibril depleted; AL amyloidosis with kidney disease)
42:03 — Other Recruiting & Planned Clinical Trials
44:05 — Treatments by light chain type/disease status
45:28 — How to find clinical trials
48:42 — Q&A Session
49:18 — How do I find out if I have lambda and kappa light chain involvement?
50:28 — How do I know if I’m relapsed or refractory?
51:53 — Is AL amyloidosis a cancer?
53:22 — If I’m newly diagnosed, should I consider going on a trial?
55:42 — Is a stem cell transplant standard of care? How does that work with clinical trials?
57:35 — Are all trials using the same levels or definitions for disease stages?
1:00:18 — How does health insurance play into clinical trials?
1:01:46 — Conclusion
Contact ARC:
Call +1 (617) 467-5170
Email ARC at support@arci.org

